Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer

Alimera Sciences announced the appointment of Russell L. Skibsted as Senior Vice President and Chief Financial Officer (CFO), effective January 9, 2023. 

“We are extremely excited to have someone of Russell’s caliber join us here at Alimera,” Rick Eiswirth, President and CEO of Alimera, said in a company news release. “His extensive tenure in multiple pharma sectors as well as his broad experience in acquisitions and licensing, capital markets, investor relations, and financial operations will help us further achieve our goal of becoming the place to be in retina. We look forward to his engagement and expertise, leveraging his background from a variety of both public and private life sciences companies, in all stages of growth from start-up through commercial stability.”

“I am really looking forward to working with the team here at Alimera and with the investment community,” said Mr. Skibsted. “I believe Iluvien is a tremendous asset in treating diabetic macular edema that helps patients see better longer, and I am thrilled to help Alimera continue its growth in the retina space”.

Mr. Skibsted is a seasoned pharma executive with nearly 30 years of experience in financial management, global business development, capital raises, investor relations, and operations. He has worked with a variety of both public and private life sciences companies at all stages of development. Prior to joining Alimera, he served as Executive Vice President, CFO and Chief Business Officer at Rockwell Medical, a public company providing hemodialysis products.